- Home
- PBYI vs MG Comparison
PBYI vs MG Comparison
Compare PBYI & MG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- MG
- Stock Information
- Founded
- PBYI 2010
- MG 1978
- Country
- PBYI United States
- MG United States
- Employees
- PBYI N/A
- MG N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- MG Military/Government/Technical
- Sector
- PBYI Health Care
- MG Consumer Discretionary
- Exchange
- PBYI Nasdaq
- MG Nasdaq
- Market Cap
- PBYI 263.4M
- MG 309.4M
- IPO Year
- PBYI N/A
- MG 2009
- Fundamental
- Price
- PBYI $4.95
- MG $11.79
- Analyst Decision
- PBYI Strong Buy
- MG
- Analyst Count
- PBYI 1
- MG 0
- Target Price
- PBYI $7.00
- MG N/A
- AVG Volume (30 Days)
- PBYI 418.9K
- MG 95.4K
- Earning Date
- PBYI 11-06-2025
- MG 11-04-2025
- Dividend Yield
- PBYI N/A
- MG N/A
- EPS Growth
- PBYI 434.29
- MG 64.89
- EPS
- PBYI 0.97
- MG 0.57
- Revenue
- PBYI $238,062,000.00
- MG $715,300,000.00
- Revenue This Year
- PBYI N/A
- MG $1.23
- Revenue Next Year
- PBYI N/A
- MG $2.80
- P/E Ratio
- PBYI $5.08
- MG $20.69
- Revenue Growth
- PBYI 8.63
- MG N/A
- 52 Week Low
- PBYI $2.32
- MG $7.06
- 52 Week High
- PBYI $6.07
- MG $11.88
- Technical
- Relative Strength Index (RSI)
- PBYI 45.94
- MG 76.54
- Support Level
- PBYI $5.14
- MG $9.45
- Resistance Level
- PBYI $5.52
- MG $9.81
- Average True Range (ATR)
- PBYI 0.25
- MG 0.35
- MACD
- PBYI -0.06
- MG 0.11
- Stochastic Oscillator
- PBYI 17.82
- MG 96.15
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.